Endometriosis IVF in Hong Kong: A Complete Process Guide

Real consultation scenario opening

Clinic Note: Consultation with a 32-year-old Endometriosis Patient

In October 2024, a 32-year-old woman arrived at the reproductive medicine clinic carrying a thick stack of medical reports. She had undergone laparoscopy in 2022 due to progressive dysmenorrhea, which confirmed Stage III endometriosis, a 4.2 cm chocolate cyst on the left ovary, and a grossly normal right ovary. Post-surgery, she received GnRH-a treatment for 3 months. After stopping medication, she attempted natural conception for 12 months without success. On day 3 of her most recent menstrual cycle, her AMH was 1.2 ng/mL, FSH 9.8 IU/L, and antral follicle count showed 2 on the left and 3 on the right. She asked directly: "Is it feasible for me to go to Hong Kong for IVF?"

This is a classic case of fertility difficulty related to endometriosis. Answering this question requires analyzing multiple dimensions: endometriosis stage, ovarian reserve, surgical history, male factors, and the differences between the Hong Kong and mainland healthcare systems. The following sections elaborate on the medical logic and practical aspects step by step.

IVF for Endometriosis Patients: A Medical Decision Framework

When is it appropriate to consider IVF directly? According to the 2022 ESHRE guideline on fertility management for endometriosis, IVF is recommended as a first- or second-line treatment in the following situations: Stage III–IV endometriosis, impaired tubal function or severe pelvic adhesions, diminished ovarian reserve (AMH < 1.5 ng/mL or AFC < 6), abnormal male semen parameters, or failure to conceive after 12 months of post-surgical attempts.

When is IVF not yet recommended? For Stage I–II endometriosis with normal ovarian reserve, patent fallopian tubes, normal male semen, and age < 35 years, continuing natural conception attempts or 2–3 cycles of intrauterine insemination (IUI) is reasonable. Additionally, if there is a large untreated chocolate cyst (> 5 cm) or an active endometrioma with signs of infection, the management of the cyst should be evaluated first.

Why does endometriosis reduce natural conception rates? The mechanisms are multifactorial: pelvic adhesions impair ovum pickup by the fallopian tubes; ovarian endometriomas compress normal ovarian cortex, reducing antral follicle density; elevated inflammatory cytokines (TNF-α, IL-6, etc.) in peritoneal fluid negatively impact oocyte quality and embryo development; and abnormal expression of genes related to endometrial receptivity interferes with embryo implantation. These combined factors reduce the monthly natural conception rate in Stage III–IV endometriosis patients to 1%–3%, far below the 15%–20% seen in age-matched healthy women.

In clinical evaluation, reproductive specialists focus on the following indicators: revised ASRM (rASRM) stage, ovarian reserve (AMH + AFC + FSH), cyst size and growth trend, number of prior surgeries (especially the impact of ovarian cystectomy on ovarian cortex), and male semen analysis and morphology. For the aforementioned 32-year-old patient, an AMH of 1.2 ng/mL corresponds to the threshold for diminished ovarian reserve (DOR). Combined with Stage III endometriosis, IVF is a reasonable next step.

Differences in Endometriosis IVF Protocols Between Hong Kong and Mainland China

Hong Kong and mainland China share the same foundational framework for assisted reproductive technology, but several differences in implementation affect the choices for endometriosis patients.

For endometriosis patients, Hong Kong offers certain features in terms of individualized ovulation stimulation protocols, conservative cyst management strategies, and accessibility to PGT technology. However, it is important to note that these differences do not mean "Hong Kong is better." Patients must weigh their specific stage, ovarian reserve, financial situation, and time constraints.

Actual IVF Process in Hong Kong: An Example for Endometriosis Patients

The process is divided into six stages, each with special considerations for endometriosis patients.

Stage 1: Initial Consultation and Medical Evaluation

• Female tests: AMH, FSH, LH, E2, P, T, PRL, TSH, CA125 (often elevated in endometriosis patients but not a diagnostic gold standard), pelvic ultrasound (to assess cyst size, location, and antral follicle count).
• Male tests: Semen analysis + morphology + DNA fragmentation index (DFI). Partners of endometriosis patients have a slightly higher probability of elevated sperm DFI, related to oxidative stress.
• Tests for both partners: Karyotype analysis, thalassemia screening (high prevalence in Guangdong, Guangxi, etc.), infectious disease screening (Hepatitis B, Hepatitis C, HIV, Syphilis), ABO blood type and Rh factor.
• Previous records: Surgical reports, pathology reports, and post-operative medication history.

Stage 2: Developing the Ovulation Stimulation Protocol

For endometriosis patients, especially those with DOR, one of the following protocols is commonly used: GnRH antagonist protocol (flexible, short cycle, lower total medication dose), PPOS protocol (uses progesterone to suppress LH surge, suitable for DOR patients), or Ultra-long protocol (GnRH-a for 2–3 months to suppress endometriosis lesions before starting stimulation, indicated for larger cysts or significant pelvic pain). The doctor selects the protocol based on cyst size, AMH level, and previous response to stimulation.

Stage 3: Egg Retrieval Surgery

During egg retrieval, if a chocolate cyst is > 3 cm in diameter and accessible, some centers may perform simultaneous cyst aspiration to reduce the cyst's compression on the ovary and lower the risk of post-retrieval infection. However, the recurrence rate after aspiration is about 30%–50%, which requires thorough discussion with the patient. After the procedure, the patient is observed for 2 hours and can return home if there is no active bleeding.

Stage 4: Embryo Culture and PGT

Embryos are cultured to the blastocyst stage on days 5–6. Embryo development in endometriosis patients may be slightly slower, so culture time should be individualized. If the patient requests PGT-A (aneuploidy screening), 5–10 trophectoderm cells are biopsied on days 5–6 for whole genome amplification and sequencing. PGT-A can reduce implantation failure due to embryonic aneuploidy but does not increase the absolute live birth rate and carries a risk of mosaicism misdiagnosis.

Stage 5: Frozen Embryo Transfer

Due to decreased endometrial receptivity in the stimulated cycle, all embryos are typically frozen for a subsequent frozen embryo transfer (FET). Before transfer, endometrial thickness, pattern, and blood flow are assessed; hysteroscopy may be performed if necessary. About 15%–25% of endometriosis patients have endometrial polyps, adhesions, or chronic endometritis, which can be addressed during hysteroscopy.

Stage 6: Luteal Phase Support

Intramuscular progesterone or vaginal progesterone gel is used, continuing until a blood β-hCG test 12–14 days after transfer. If pregnancy continues, luteal support is maintained until 10–12 weeks of gestation. Endometriosis patients have a slightly higher incidence of luteal phase deficiency, so the dose and duration of luteal support should be individualized.

Timeline and Number of Visits to Hong Kong

The overall cycle takes about 2–4 months, depending on the stimulation protocol, whether PGT is performed, and the transfer cycle arrangement.

Note: Hong Kong requires that medications used during stimulation be prescribed by a registered doctor. Some medications may be purchased in mainland China and carried via cold chain, but customs regulations must be confirmed in advance. If the PPOS protocol is chosen, the stimulation period can be shortened to 10–12 days, but more frequent monitoring visits are needed.

Cost Structure and Influencing Factors

The cost of IVF in Hong Kong varies significantly depending on the hospital, protocol, use of PGT, and medication source. The following are reference ranges (in HKD):

• Basic tests: 15,000–25,000 (includes blood tests for both partners, ultrasound, semen analysis, chromosomes, etc.)
• Ovulation stimulation medications: 25,000–50,000 (imported recombinant FSH + GnRH antagonist; dosage varies; higher doses needed for low AMH)
• Egg retrieval + embryo culture: 40,000–60,000 (includes retrieval, ICSI fertilization, blastocyst culture)
• PGT-A/PGT-M cost: 30,000–50,000 (per embryo batch; typically up to 5 embryos per unit)
• Frozen embryo transfer: 15,000–25,000 (includes endometrial preparation medication + transfer procedure)
• Embryo freezing: 4,000–6,000/year

The total cost typically ranges from 150,000 to 250,000 HKD, increasing to 200,000–300,000 HKD if PGT is used. Factors influencing cost include: hospital brand (e.g., Hong Kong Sanatorium & Hospital, Union Hospital, Gleneagles Hong Kong Hospital have different pricing), medication dosage (higher for DOR patients), need for a second stimulation cycle, and exchange rate fluctuations. Some costs may be settled in USD (e.g., imported PGT reagent kits), so confirmation with the hospital in advance is recommended.

Frequently Asked Questions

Q1: What is the IVF success rate for endometriosis patients in Hong Kong?

The success rate is highly correlated with age, ovarian reserve, endometriosis stage, and previous pregnancy history; there is no fixed "endometriosis IVF success rate." According to 2023 data from the Hong Kong Council on Human Reproductive Technology (HTA): for autologous IVF, the live birth rate per transfer cycle is approximately 38%–45% for women under 35, 30%–38% for ages 35–38, and 18%–25% for ages 39–42. Patients with Stage III–IV endometriosis have a live birth rate 8%–12% lower than age-matched non-endometriosis patients, primarily due to reduced oocyte quality and implantation rates. However, if AMH > 1.5, age < 35, and cysts are managed appropriately, the live birth rate can approach that of non-endometriosis peers.

Q2: Do I need surgery in mainland China before going to Hong Kong for IVF?

Not necessarily. For chocolate cysts < 4 cm in diameter without significant pain and not interfering with egg retrieval, priority can be given to egg retrieval with cyst aspiration. If the cyst is > 5 cm, or associated with persistent pain, or ultrasound shows septations or solid components, it is recommended to first undergo a pelvic MRI in Hong Kong for evaluation by both a reproductive specialist and a gynecologist to decide on surgery. Avoid repeat laparoscopic cystectomy before IVF, as it can further reduce ovarian reserve.

Q3: What documents are needed for IVF in Hong Kong?

Valid Mainland Travel Permits for Hong Kong and Macao (with valid endorsements for individual travel or medical treatment, depending on local exit-entry policies) for both partners; original and copy of marriage certificate (some hospitals require notarization or translation); previous medical records and test reports from a mainland tertiary hospital (must be translated into English or Traditional Chinese); some hospitals require a referral letter in a specific format. It is advisable to check the validity of endorsements 2 months in advance. Medical endorsements for Hong Kong typically allow a stay of 14–30 days.

Q4: What preparations should endometriosis patients make before IVF?

Supplement folic acid 400–800 μg/day (standard preconception care). For those with vitamin D < 30 ng/mL, supplement vitamin D 2000 IU/day. Coenzyme Q10 200–400 mg/day (to improve oocyte mitochondrial function; moderate level of evidence). Adopt a Mediterranean diet (high in vegetables, fruits, whole grains, olive oil, fish), and reduce red meat and processed foods. Avoid self-administering high-dose hormonal agents like DHEA, as endometriosis is an estrogen-dependent disease. An elevated CA125 does not mean IVF cannot proceed; it should be interpreted in conjunction with imaging and symptoms.

Management of Special Situations

Poor Ovarian Response (POR): If fewer than 3 oocytes were retrieved in the previous cycle, consider switching to a PPOS or mild stimulation protocol in the next cycle, or try adding growth hormone (GH). Some centers in Hong Kong offer LH addition protocols, suitable for DOR patients with high FSH and low LH.

Deep Infiltrating Endometriosis (DIE): If there is involvement of the rectovaginal septum or ureter, a gynecologist should evaluate whether surgical resection of the lesion is needed before IVF. However, DIE surgery carries high risks (bowel injury, ureteral injury) and offers limited improvement in post-surgical pregnancy rates. In most cases, priority can be given to oocyte retrieval and embryo freezing, with DIE lesion management deferred until after childbearing is complete.

Recurrent Implantation Failure (RIF): For endometriosis patients who have failed to implant after 2 or more transfers of good-quality embryos, it is recommended to perform hysteroscopy with endometrial biopsy (CD138 staining to rule out chronic endometritis), ERA testing (endometrial receptivity analysis, though evidence is still debated), and PGT-A to exclude embryonic factors. ERA and EMT (endometrial microbiome analysis) are available in Hong Kong but are self-funded, with an improvement rate of approximately 15%–20% in pregnancy outcomes.

Risk Reminders

Endometriosis patients undergoing IVF should be aware of the following medical risks:

• Ovarian Hyperstimulation Syndrome (OHSS): Due to the characteristics of the pelvic microenvironment, the risk of OHSS in endometriosis patients is not significantly different from the general population, but the risk is higher in those with concurrent PCOS. Using a GnRH antagonist protocol with a GnRH-a trigger can significantly reduce the risk of OHSS.
• Cyst infection or rupture: Aspiration of a cyst during egg retrieval can lead to cyst fluid leakage, pelvic infection, or acute abdomen, with an incidence of about 1%–3%. Prophylactic antibiotics should be used before the procedure, and patients should be closely monitored for abdominal pain and fever afterward.
• Further decline in ovarian reserve: Ovulation stimulation medications themselves do not accelerate ovarian aging, but the aspiration or stripping of a cyst during retrieval may result in the loss of a small amount of normal ovarian cortex. For patients with AMH < 0.5, the sequence of oocyte retrieval and cyst management should be discussed with the doctor.
• Pregnancy risks: Endometriosis patients have higher rates of preterm birth, placenta previa, and cesarean section in natural pregnancies; these risks persist in IVF pregnancies, with added risks from multiple gestations. Single embryo transfer is recommended to reduce obstetric complications.
• Financial risk: The cost of IVF in Hong Kong is high, and if a cycle does not result in a live birth, the full cost of a subsequent cycle must be prepared again. It is advisable to confirm with the hospital whether multi-cycle packages or refund plans are available and to assess your own financial capacity before starting.

All assisted reproductive decisions should be based on the patient's individual circumstances, medical evidence, and full informed consent. The content of this article does not constitute medical advice. Specific plans should be developed by a reproductive medicine specialist based on the patient's complete medical history.